Orders from 190 AUD Free delivery from 395 AUD Ready for pickup dead drop: collect in 5 min

Substances · Benzodiazepines and thienodiazepines

Flubromazepam

C15H10BrFN2O CAS 2647-50-9 Analytical reference material — not for human consumption
Preferred name
Flubromazepam
IUPAC name
7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
Parent CAS number (reference)
2647-50-9
Molecular formula
C15H10BrFN2O
Molecular weight
333.15 g/mol
InChIKey
ZRKDDZBVSZLOFS-UHFFFAOYSA-N
PubChem
CID 12947024
Source
PubChem
Verified synonyms & catalog abbreviations
Ro 05-2904 7-Bromo-2'-fluorodesmethyldiazepam

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

Flubromazepam

Ultra-Long Half-Life GABA-A PAM 1,4-Benzodiazepine
Verified PubChem & CAS Identity C15H10BrFN2O · CAS 2647-50-9 · CID 12947024
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 333.15 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Very High
GABAₐ α₅ Amnestic / Cognitive Modulation High

7-Bromo-2'-fluoro-1,4-benzodiazepin-2-one acting as a classic full GABA-A PAM with an elimination half-life exceeding 100 hours in human pharmacokinetic studies.

Biotransformation & Active Metabolites

Human pharmacokinetic study (Moosmann et al.) documents a ~106-hour terminal half-life via monohydroxylated metabolites.

Temporal Pharmacokinetics

Ultra-Long Half-Life GABA-A PAM — Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

  1. Onset 45–120 min
  2. Peak Window 3–6 h
  3. Total Window 12–24 h
  4. Residual / Half-Life 36–72+ h residual (T1/2 ~106 h)

Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
2 mg
Cognitive & Sensory

Subtle threshold receptor activity (Ultra-Long Half-Life GABA-A PAM).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
2–4 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
4–8 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
8–12 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
14+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance.

Physicochemical Stability & Storage

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Comprehensive Analytical & Toxicological Monograph

Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one; CAS 2647-50-9, PubChem CID 12947024) is a 1,4-benzodiazepine reference compound (C15H10BrFN2O, 333.15 g/mol) classified pharmacologically as a Ultra-Long Half-Life GABA-A PAM. 7-Bromo-2'-fluoro-1,4-benzodiazepin-2-one acting as a classic full GABA-A PAM with an elimination half-life exceeding 100 hours in human pharmacokinetic studies. Human pharmacokinetic study (Moosmann et al.) documents a ~106-hour terminal half-life via monohydroxylated metabolites. In published observational and toxicological literature, threshold response is noted at 2 mg, light range at 2–4 mg, common reference range at 4–8 mg, strong intensity at 8–12 mg, and heavy/adverse territory at 14+ mg, with an onset of 45–120 min, peak window of 3–6 h, and total duration of 12–24 h (36–72+ h residual (T1/2 ~106 h)). Lower milligram potency per 1 mg tablet (common literature range 4–8 mg), but extreme ~106 h half-life means slow onset (up to 2 h) and severe multi-day accumulation hazard if repeated before clearance. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Flubromazepam (7-bromo-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C15H10BrFN2O and a molar mass of 333.15 g/mol. The parent molecule is indexed under CAS registry number 2647-50-9 and in the NCBI PubChem database as CID 12947024 (Standard InChIKey: ZRKDDZBVSZLOFS-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Flubromazepam is indexed within the Benzodiazepines structural group. Toxicological notes (PsychonautWiki): low toxicity, potentially lethal when mixed with depressants like alcohol or opioids. Dependence liability (PsychonautWiki): extremely physically and psychologically addictive. Documented cross-tolerance class: benzodiazepines. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations